Belgium · Delayed Price · Currency is EUR Celyad Oncology Company Description
Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.
It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the T-cell receptor (TCR) without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-cells.
It also engages in the development of CYAD-01, a CAR T-cell product candidate based on the natural killer group 2D (NKG2D); CYAD-02, an autologous NKG2D-based CAR T-cell candidate used to target the NKG2D ligands (NKG2DL) MICA/B to prevent cell fratricide and improve cell persistence; and CYAD-211, an allogeneic B-cell maturation antigen (BCMA)-targeting CAR T-cell candidate.
In addition, the company offers C-Cathez, an intra-myocardial injection catheter. It has a license agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; research and development collaboration, and license agreements with Hr for the use of shRNA to downregulate such targets in immune cells and the combination of shRNAs with a chimeric antigen receptor in immune cells; and a license agreement with Mesoblast to develop and commercialize C-Cathez.
The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
| Country | Belgium |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Matthew Kane |
Contact Details
Address: Axis Business Park Mont-Saint-Guibert, 1435 Belgium | |
| Phone | 32 1 039 41 00 |
| Website | celyad.com |
Stock Details
| Ticker Symbol | CYAD |
| Exchange | Euronext Brussels |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | BE0974260896 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Matthew R. Kane | Chief Executive Officer and Executive Director |
| Michel E. J. Lussier BME, M.B.A., M.S., MS BME | Co-Founder and Non-Executive Director |
| David Georges | Vice President of Finance and Administration |
| Sara Zelkovic | Communications and Investor Relations Director |
| An Phan | Head of Legal |
| Hannes Iserentant | Head of Intellectual Property |
| Eytan Breman | Head of Research & Development |
| Philippe Dechamps | Corporate Secretary |